Related Experiment Video

Updated: May 22, 2026

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells

Kuan-Der Lee1, Mei-Yu Pai, Chia-Chen Hsu

  • 1Department of Hematology and Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan.

Biochemical and Biophysical Research Communications
|May 19, 2012
PubMed

Insights

Abnormal DNA methylation of Casp8AP2 promoter contributes to cancer drug resistance. Targeting this epigenetic modification may offer new strategies for overcoming resistance in cancer therapy.

Area of Science:

  • Molecular biology
  • Epigenetics
  • Cancer research

Background:

  • Casp8AP2 is crucial for cell death signaling and its genetic defects are linked to diseases.
  • Aberrant DNA methylation of the Casp8AP2 promoter is observed in cancers.
  • The role of Casp8AP2 promoter methylation in cancer drug resistance is unclear.

Purpose of the Study:

  • To investigate the hypothesis that abnormal DNA methylation of the Casp8AP2 promoter contributes to prolonged cellular survival or drug resistance in cancer.
  • To determine the epigenetic state of the Casp8AP2 promoter in various cancer cell lines and patient samples.
  • To assess whether targeted Casp8AP2 methylation promotes drug resistance.

Main Methods:

  • Methylation-specific PCR was used to analyze the epigenetic state of the Casp8AP2 promoter in cancer cell lines and patient samples.
  • Targeted Casp8AP2 methylation was performed in somatic stem cells and cancer cells.
  • Global demethylation was induced in a platinum drug-resistant gastric cancer cell line.

Main Results:

  • Differential Casp8AP2 methylation was observed between normal and tumoral samples.
  • Global demethylation in a resistant gastric cancer cell line reversed Casp8AP2 methylation and reduced drug resistance.
  • Targeted methylation of the Casp8AP2 promoter increased resistance to drugs, including platinum agents, in somatic stem cells and cancer cells.

Conclusions:

  • DNA methylation within the Casp8AP2 promoter correlates with the development of drug resistance in cancer.
  • Casp8AP2 promoter methylation may serve as a potential biomarker for cancer drug resistance.
  • Targeting Casp8AP2 methylation presents a potential therapeutic strategy for overcoming drug resistance in cancer.

More Related Videos

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches05:56

Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches

Published on: October 13, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...